Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations

Mukherji, Deborah; Youssef, Bassem; Dagher, Christelle; Hajj, Albert El; Nasr, Rami; Geara, Fadi; Rabah, Danny; Dousari, Saad Al; Said, Rabih; Ashou, Raja; Wazzan, Wassim; Jabbour, Michel E.; Farha, George J.; Hamdani, Nibras Al; Hallaq, Yousuf Al; Ghazal, Hassan; Dbouk, Haifa; Bachir, Bassel G.; Khoury, C. El; Sakr, Ghazi; Hussain, Hero K.; Sayyid, Khaled; Ibrahim, Khaled; Haidar, Mohammad A.; Zouain, Nicolas; Bitar, Nizar; Alameh, Walid; Abbas, Fadi; Faddoul, Sami; Nemer, Elie; Assaf, Georges; Farhat, Fadi; Bulbul, Muhammad; Temraz, Sally; Shamseddine, Ali; Gillessen, Silke; Omlin, Aurelius; Khauli, Raja B.

doi:10.1007/s00345-019-02872-x

Cited by 16 publications

(15 citation statements)

References 42 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many cases cancer incidence and particularly mortality data are derived from modelled estimates rather than verified clinical records [ 5 ]. With most countries in the Arab world undergoing demographic transition resulting in population ageing plus improved access to diagnostic testing, regional prostate cancer incidence is increasing, as is the need for context-specific research [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer in the Arab world: Bibliometric review and research priority recommendations

Ali

Awada

Nassereldine

et al. 2022

Arab Journal of Urology

Self Cite

View full text Add to dashboard Cite

Objective To conduct a scoping review examining the status of prostate cancer research in Arab countries and systematically map publications across the cancer care pathway. Prostate cancer incidence has been rising in the Arab world and tackling its increasing burden will require evidence-based policies. Methods We searched Medline, PubMed and Scopus for peer-reviewed publications related to both our research topic and countries of interest by using controlled vocabulary and keywords. Search results were limited for the period between 2000 and 2020, screened for duplicates, and then included in our study based on pre-specified eligibility criteria. We used a structured data extraction form to extract information related to the article, its methodology, its cancer care pathway, funding status, and authorship. Results A total of 4142 publications were retrieved from our search, of which 874 articles remained after applying eligibility criteria. Trends show a steady increase in prostate cancer research in the Arab world. Most studies were focussed on diagnosis and treatment, whereas a lack in studies concerning screening and prevention, as well as epidemiological data, was evident. Most studies were not funded and had no female author. Country gross domestic product and population were positively correlated with its research output. The USA had the highest number of corresponding authors. The majority of Arab-based studies did not involve collaborations with other countries. Most research conducted was basic or clinical studies with a low level of evidence. Conclusion Our present review identified significant gaps and limitations in prostate cancer research in Arab countries. Priority areas for research investment have also been highlighted as a first step towards context-specific health policies. Abbreviations ASR: age-standardised rate; COVID-19: coronavirus disease 2019; GDP: gross domestic product; HDI: Human Development Index; KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates

show abstract

Section: Introductionmentioning

confidence: 99%

Prostate cancer in the Arab world: Bibliometric review and research priority recommendations

Ali

Awada

Nassereldine

et al. 2022

Arab Journal of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The burden of PCa varied significantly among the countries, which could be due to limited awareness and variable coverage of screenings in the region, along with the divergent development of cancer registries ( 21 ). There was a six-fold gap between Algeria, with the lowest PCa incidence, and Lebanon, which had the highest.…”

Section: Discussionmentioning

confidence: 99%

The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study

et al. 2022

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019.MethodsThis study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment.ResultsThe age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively.ConclusionsThe PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.

show abstract

“…Our group have recently reported the first regional consensus on resource-stratified prostate cancer management in the ME. [ 25 ]…”

Section: Discussionmentioning

confidence: 99%

High rates of advanced prostate cancer in the Middle East

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objectives: Prostate cancer incidence is increasing in the Middle East (ME); however, the data of stage at the diagnosis and treatment outcomes are lacking. In developed countries, the incidence of de novo metastatic prostate cancer ranges between 4% and 14%. We hypothesized that the rates of presentation with advanced disease are significantly higher in the ME based on clinical observation. This study aims to examine the stage at the presentation of patients with prostate cancer at a large tertiary center in the ME. Methods: After Institutional Review Board approval, we identified the patients diagnosed with prostate adenocarcinoma and presented to a tertiary care center between January 2010 and July 2015. Clinical, demographic, and pathological characteristics were abstracted. Patients with advanced disease were stratified according to tumor volume based on definitions from practice changing clinical trials. Descriptive and Kaplan–Meier survival analysis was used. Results: A total of 559 patients were identified, with a median age at the diagnosis of 65 years and an age range of 39–94 years. Median prostate-specific antigen (PSA) at the presentation was 10 ng/ml, and almost a quarter of the men (23%) presented with metastatic disease. The most common site of metastasis was the bone (34/89, 38%). High-volume metastasis was present in 30.3%, 9%, and 5.2% of the cohort based on STAMPEDE, CHAARTED, and LATITUDE trial criteria, respectively. Conclusion: This is the first report showing the high proportion of men from ME presenting with de novo metastasis. This could be due to many factors, including the highly variable access to specialist multidisciplinary management, lack of awareness, and lack of PSA screening in the region. There is a clear need to raise the awareness about prostate cancer screening and early detection and to address the rising burden of advanced prostate cancer affecting men in the ME region.

show abstract

Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations

Cited by 16 publications

References 42 publications

Prostate cancer in the Arab world: Bibliometric review and research priority recommendations

Prostate cancer in the Arab world: Bibliometric review and research priority recommendations

The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study

High rates of advanced prostate cancer in the Middle East

Contact Info

Product

Resources

About